Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPR3 | P17342 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18474776 | 0.90 | NPR3 (0.32) | NPR3 | |
| SCHEMBL24235913 | 0.89 | NPR3 (0.34) | NPR3FOLH1 | |
| SCHEMBL19590210 | 0.84 | NPR3 (0.32) | NPR3 | |
| SCHEMBL790384 | 0.83 | NPR3 (0.41) | NPR3FOLH1MEN1ALDH1A1LMNA | |
| SCHEMBL790021 | 0.83 | NPR3 (0.41) | NPR3FOLH1MEN1ALDH1A1LMNA | |
| SCHEMBL789730 | 0.83 | NPR3 (0.41) | NPR3FOLH1MEN1ALDH1A1LMNA | |
| SCHEMBL19861842 | 0.77 | FOLH1 (0.35) | NPR3FOLH1MEN1ALDH1A1LMNA | |
| SCHEMBL22503353 | 0.77 | NPR3 (0.35) | NPR3FOLH1MEN1ALDH1A1LMNA | |
| SCHEMBL19335106 | 0.76 | — | — | |
| SCHEMBL18474777 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-18 | — | — | US | disclosed |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | JANSSEN BIOPHARMA, LLC | 2020-12-17 | — | — | US | disclosed |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-10370401-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190031703-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-01-31 | — | — | US | disclosed |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472826-B2 | Acyclic antivirals | PNP, DUT, TYMP | NPR3 3002/4885FOLH1 1280/4885MEN1 3250/4885 |
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, TYMP | NPR3 1160/4885FOLH1 1215/4885MEN1 4072/4885 |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | NPR3 1072/4885FOLH1 1575/4885MEN1 3891/4885 |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | NPR3 1160/4885FOLH1 1215/4885MEN1 4072/4885 |
| US-20200392169-A1 | ACYCLIC ANTIVIRALS | PNP, DUT, TYMP | NPR3 3002/4885FOLH1 1280/4885MEN1 3250/4885 |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | NPR3 1135/4885FOLH1 409/4885MEN1 3523/4885 |
| US-10370401-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, NUDT1 | NPR3 1072/4885FOLH1 1575/4885MEN1 3891/4885 |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | NPR3 1734/4885FOLH1 749/4885MEN1 3311/4885 |
| US-20190031703-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | NPR3 1695/4885FOLH1 1161/4885MEN1 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.